HRP20100402T1 - Formamide derivatives useful as adrenoceptor - Google Patents

Formamide derivatives useful as adrenoceptor Download PDF

Info

Publication number
HRP20100402T1
HRP20100402T1 HR20100402T HRP20100402T HRP20100402T1 HR P20100402 T1 HRP20100402 T1 HR P20100402T1 HR 20100402 T HR20100402 T HR 20100402T HR P20100402 T HRP20100402 T HR P20100402T HR P20100402 T1 HRP20100402 T1 HR P20100402T1
Authority
HR
Croatia
Prior art keywords
hydroxyphenyl
formylamino
hydroxyethylamino
methylpropyl
phenyl
Prior art date
Application number
HR20100402T
Other languages
Croatian (hr)
Inventor
Daniel Brown Alan
Edward Bunnage Mark
Alan Glossop Paul
James Kim
Alice Louise Lane Charlotte
Andrew Lewthwaite Russell
Anthony Price David
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2005/000619 external-priority patent/WO2005092840A1/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20100402T1 publication Critical patent/HRP20100402T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/42—Y being a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Spoj opće formule (1), naznačen time što skupina (CH2)n-C(=O)Q1 je na meta ili para položaju,- R1 i R2 se neovisno bira između H i C1-C4 alkila;- n je 0, 1 ili 2;- Q1 je skupina koju se bira između, gdje p je 1 ili 2, a q je 1 ili 2, gdje je navedena skupina izborno premoštena s jednim atomom ugljika, i skupine *-NR8-Q2-A, gdje Q2 je C1-C4 alkilen, R8 je H ili C1-C4 alkil, a A je piridil, C3-C10 cikloalkil, gdje je navedeni cikloalkil izborno premošten s jednim ili više atoma ugljika, tetrahidropiranil, piperidinil, tetrahidrotiopiranil ili skupina- R3, R4, R5, R6 i R7 su isti ili različiti i bira ih se između H, C1-C4 alkila, OR9, SR9, SOR9, SO2R9, halogena, CO2R9 CF3, CN, OCF3, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 i fenila, izborno supstituiranog s 1 do 3 skupine, koje se bira između OR9, halogena i C1-C4 alkila;- R9 i R10 su isti ili različiti i bira ih se između H ili C1-C4 alkil, a * predstavlja točku vezanja na karbonilnu skupinu; ili, ako je to prikladno, njegove farmaceutski prihvatljive soli i/ili izomeri, tautomeri, solvati ili njihove izotopne varijante. Patent sadrži još 23 patentna zahtjeva.A compound of general formula (1), wherein the group (CH 2) n C (= O) Q 1 is in the meta or para position, - R 1 and R 2 are independently selected from H and C 1 -C 4 alkyl, - n is 0, 1 or 2 Q1 is a group selected from, wherein p is 1 or 2, aq is 1 or 2, wherein said group is optionally bridged by one carbon atom, and the group * -NR8-Q2-A, wherein Q2 is C1-C4 alkylene, R8 is H or C1-C4 alkyl, and A is pyridyl, C3-C10 cycloalkyl, wherein said cycloalkyl is optionally bridged with one or more carbon atoms, tetrahydropyranyl, piperidinyl, tetrahydrothiopyranyl or a group- R3, R4, R5, R6 and R7 are the same or different and are selected from H, C1-C4 alkyl, OR9, SR9, SOR9, SO2R9, halogen, CO2R9 CF3, CN, OCF3, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 and phenyl, optionally substituted with 1 to 3 groups selected from OR9, halogen and C1-C4 alkyl - R9 and R10 are the same or different and are selected from H or C1-C4 alkyl, and * represents the point of attachment to the carbonyl group; or, if appropriate, pharmaceutically acceptable salts and / or isomers, tautomers, solvates or isotopic variants thereof. The patent contains another 23 patent claims.

Claims (24)

1. Spoj opće formule (1), [image] naznačen time što skupina (CH2)n-C(=O)Q1 je na meta ili para položaju, – R1 i R2 se neovisno bira između H i C1-C4 alkila; – n je 0, 1 ili 2; – Q1 je skupina koju se bira između, [image] gdje p je 1 ili 2, a q je 1 ili 2, gdje je navedena skupina izborno premoštena s jednim atomom ugljika, [image] i skupine *-NR8-Q2-A, gdje Q2 je C1-C4 alkilen, R8 je H ili C1-C4 alkil, a A je piridil, C3-C10 cikloalkil, gdje je navedeni cikloalkil izborno premošten s jednim ili više atoma ugljika, tetrahidropiranil, piperidinil, tetrahidrotiopiranil ili skupina [image] – R3, R4, R5, R6 i R7 su isti ili različiti i bira ih se između H, C1-C4 alkila, OR9, SR9, SOR9, SO2R9, halogena, CO2R9 CF3, CN, OCF3, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 i fenila, izborno supstituiranog s 1 do 3 skupine, koje se bira između OR9, halogena i C1-C4 alkila; – R9 i R10 su isti ili različiti i bira ih se između H ili C1-C4 alkil, a * predstavlja točku vezanja na karbonilnu skupinu; ili, ako je to prikladno, njegove farmaceutski prihvatljive soli i/ili izomeri, tautomeri, solvati ili njihove izotopne varijante.1. Compound of general formula (1), [image] characterized by the fact that the group (CH2)n-C(=O)Q1 is in the meta or para position, – R1 and R2 are independently selected from H and C1-C4 alkyl; – n is 0, 1 or 2; – Q1 is a group to choose from, [image] where p is 1 or 2 and q is 1 or 2, wherein said group is optionally bridged with one carbon atom, [image] and groups *-NR8-Q2-A, where Q2 is C1-C4 alkylene, R8 is H or C1-C4 alkyl, and A is pyridyl, C3-C10 cycloalkyl, where said cycloalkyl is optionally bridged with one or more carbon atoms, tetrahydropyranyl, piperidinyl, tetrahydrothiopyranyl or group [image] – R3, R4, R5, R6 and R7 are the same or different and are selected from H, C1-C4 alkyl, OR9, SR9, SOR9, SO2R9, halogen, CO2R9 CF3, CN, OCF3, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 and phenyl, optionally substituted with 1 to 3 groups, selected from OR 9 , halogen and C 1 -C 4 alkyl; – R9 and R10 are the same or different and are chosen from H or C1-C4 alkyl, and * represents the point of attachment to the carbonyl group; or, if appropriate, its pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variants thereof. 2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što Q1 je skupina *-NH-Q2-A, gdje A je cikloheksil ili adamantil.2. A compound according to claim 1, characterized in that Q1 is the group *-NH-Q2-A, where A is cyclohexyl or adamantyl. 3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što Q1 je skupina *-NH-Q2-A, gdje A je skupina [image] gdje R3, R4, R5, R6 i R7 su isti ili različiti i bira ih se između H, C1-C4 alkila, OR9, SR9, SOR9, SO2R9, halogena, CN, CO2R9, CF3, OCF3, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 i fenila, izborno supstituiranog s 1 do 3 skupine, koje se bira između OR9, halogena i C1-C4 alkila, uz uvjet da najmanje 2 od R3 do R7 su H; gdje R9 i R10 su isti ili različiti i bira ih se između H ili C1-C4 alkila.3. A compound according to claim 1, characterized in that Q1 is a group *-NH-Q2-A, where A is a group [image] where R3, R4, R5, R6 and R7 are the same or different and are selected from H, C1-C4 alkyl, OR9, SR9, SOR9, SO2R9, halogen, CN, CO2R9, CF3, OCF3, SO2NR9R10, CONR9R10, NR9R10, NHCOR 10 and phenyl, optionally substituted with 1 to 3 groups, selected from OR 9 , halogen and C 1 -C 4 alkyl, provided that at least 2 of R 3 to R 7 are H; where R9 and R10 are the same or different and are selected from H or C1-C4 alkyl. 4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što Q1 je skupina *-NH-Q2-A, gdje A je skupina [image] gdje R3, R4, R5, R6 i R7 su isti ili različiti i bira ih se između H, OH, CH3, OCH3, OCF3, OCH2-CH3, SCH3, N(CH3)2, N(C=O)CH3, C(=O)NH2, COOCH3, SO2CH3 SO2NH2, CN, halogena, CF3, te fenila, izborno supstituiranog s OH.4. A compound according to claim 3, characterized in that Q1 is a *-NH-Q2-A group, where A is a group [image] where R3, R4, R5, R6 and R7 are the same or different and are selected from H, OH, CH3, OCH3, OCF3, OCH2-CH3, SCH3, N(CH3)2, N(C=O)CH3, C (=O)NH2, COOCH3, SO2CH3 SO2NH2, CN, halogen, CF3, and phenyl, optionally substituted with OH. 5. Spoj u skladu s patentnim zahtjevom 1, naznačen time što A je skupina [image] gdje jedan od R3 do R7 je OH ili fenil supstituiran s OH.5. A compound according to claim 1, characterized in that A is a group [image] wherein one of R3 to R7 is OH or phenyl substituted with OH. 6. Spoj u skladu s patentnim zahtjevom 1, naznačen time što A je naftil, izborno suspstituiran s OH.6. A compound according to claim 1, characterized in that A is naphthyl, optionally substituted with OH. 7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što Q2 je -CH2-, -(CH2)2-, -(CH2)3-, -CH2-C(CH3)2- ili -C(CH3)2-.7. A compound according to any one of claims 1 to 6, characterized in that Q2 is -CH2-, -(CH2)2-, -(CH2)3-, -CH2-C(CH3)2- or -C (CH3)2-. 8. Spoj u skladu s patentnim zahtjevom 7, naznačen time što Q2 je -CH2-.8. A compound according to claim 7, characterized in that Q2 is -CH2-. 9. Spoj u skladu s patentnim zahtjevom 1, naznačen time što Q1 je [image] gdje R3, R4, R5 i R6 su H.9. A compound according to claim 1, characterized in that Q1 is [image] where R3, R4, R5 and R6 are H. 10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što R1 je H ili C1-C4 alkil i R2 je C1-C4 alkil.10. A compound according to any one of claims 1 to 9, characterized in that R1 is H or C1-C4 alkyl and R2 is C1-C4 alkyl. 11. Spoj u skladu s patentnim zahtjevom 10, naznačen time što R1 je H ili CH3 i R2 je H ili CH3.11. A compound according to claim 10, characterized in that R1 is H or CH3 and R2 is H or CH3. 12. Spoj u skladu s patentnim zahtjevom 1 do 11, naznačen time što n je 0 ili 1.12. A compound according to claim 1 to 11, characterized in that n is 0 or 1. 13. (R,R)-Stereoizomer, naznačen time što je stereoizomer spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 12.13. (R,R)-Stereoisomer, characterized in that the stereoisomer of the compound is in accordance with any one of patent claims 1 to 12. 14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što (CH2)n-C(=O)Q1 skupina je na meta položaju.14. A compound according to any one of claims 1 to 13, characterized in that the (CH2)n-C(=O)Q1 group is in the meta position. 15. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine N-Benzil-2-(3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; N-(3,4-Dimetilbenzil)-2-(3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; N-[2-(4-Klorfenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; N-[2-(2-Klorfenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(2-naftalen-1-iletil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-metilfenil)etil]benzamid; N-[2-(2,6-Dimetilfenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; N-[2-(2,3-Dimetilfenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropilbenzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-hidroksi-2,3-dimetilfenil)etil]benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-metoksifenil)etil]benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-fenetilbenzamid; N-Cikloheksilmetil-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; N-[5-((1R)-2-{1,1-Dimetil-2-[3-(piperidine-1-karbonil)fenil]etilamino}-1-hidroksietil)-2-hidroksifenil]formamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(3-trifluorometilfenil)etil]benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(3-fenilpropil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-indan-2-ilbenzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(2-piridin-2-iletil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksicyfenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-sulfamoilfenil)etil]benzamid; N-(4-Dimetilaminobenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; N-[5-(2-{(1R)-2-[3-(3,4-Dihidro-1H-izokinoline-2-karbonil)fenil]-1,1-dimetiletilamino}-1-hidroksietil)-2-hidroksifenil]formamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(4'-hidroksibifenil-3-ilmetil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-hidroksi-2,5-dimetilfenil)etil]benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-hidroksi-3-metilfenil)etil]benzamid; N-(4-Acetilaminobenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; 4-{[2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetilamino]metil}benzamid; N-Adamantan-1-il-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(2-hidroksinaftalen-1-ilmetil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(4-hidroksi-3,5-dimetilbenzil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(6-hidroksinaftalen-2-ilmetil)benzamid; N-(3,6-Diklor-2-hidroksibenzil)-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; N-(3,4-Dimetilbenzil)-2-(3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]etil}fenil)acetamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-hidroksifenil)-2-metilpropil]benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(4'-hidroksibifenil-4-ilmetil)benzamid; N-Adamantan-1-il-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; N-[5-(2-{2-[3-(10-Azatriciklo[6.3.1.02,7]dodeka-2(7),3,5-trien-10-karbonil)fenil]-1,1-dimetiletilamino}-1-hidroksietil)-2-hidroksifenil]formamid; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(4'-hidroksibifenil-3-ilmetil)acetamid; Metilni ester 4-{[2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetilamino]metil}benzojeve kieseline; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4-trifluorometoksibenzil)acetamid; N-(2-Klor-4-hidroksibenzil)-N-etil-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; N-(2-Klor-4-hidroksibenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(4-hidroksi-3,5-dimetilbenzil)acetamid; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(2-hidroksinaftalen-1-ilmetil)acetamid; N-(5-Klor-2-hidroksibenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; N-(3,5-Diklor-2-hidroksibenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(6-hidroksinaftalen-2-ilmetil)acetamid; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(4'-hidroksibifenil-4-ilmetil)acetamid; N-(4-Cijanobenzil)-2-(3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4-methanesulfonilbenzil)acetamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4-metilsulfanilbenzil)acetamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4-trifluorometilbenzil)acetamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4'-hidroksibifenil-4-ilmetil)acetamid; N-[2-(5-Klor-2-hidroksifenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4'-hidroksibifenil-3-ilmetil)acetamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}-N-[2-(4-hidroksifenil)-2-metilpropil]benzamid; N-(2-Klor-4-hidroksibenzil)-2-(3-{(2R)-2-[(2R)-(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; N-[2-(5-Klor-2-hidroksifenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}-N-[2-(4-hidroksifenil)-2-metilpropil]benzamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(tetrahidro-tiopiran-4-il)acetamid; N-(5-Klor-2-hidroksibenzil)-2-(3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; i N-{5-[(1R)-2-((1R)-2-{3-[3-(3,4-Dihidro-1H-izokinolin-2-il)-3-oksopropil]fenil}-1-metiletilamino)-1-hidroksietil]-2-hidroksifenil}formamid.15. A compound according to claim 1, characterized in that it is selected from the group consisting of N-Benzyl-2-(3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)acetamide; N-(3,4-Dimethylbenzyl)-2-(3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)acetamide; N-[2-(4-Chlorophenyl)ethyl]-3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}benzamide; N-[2-(2-Chlorophenyl)ethyl]-3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-(2-naphthalene-1-ylethyl)benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-[2-(4-methylphenyl)ethyl]benzamide; N-[2-(2,6-Dimethylphenyl)ethyl]-3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}benzamide; N-[2-(2,3-Dimethylphenyl)ethyl]-3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropylbenzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-[2-(4-hydroxy-2,3-dimethylphenyl)ethyl] benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-[2-(4-methoxyphenyl)ethyl]benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-phenethylbenzamide; N-Cyclohexylmethyl-3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}benzamide; N-[5-((1R)-2-{1,1-Dimethyl-2-[3-(piperidine-1-carbonyl)phenyl]ethylamino}-1-hydroxyethyl)-2-hydroxyphenyl]formamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-[2-(3-trifluoromethylphenyl)ethyl]benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-(3-phenylpropyl)benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-indan-2-ylbenzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-(2-pyridin-2-ylethyl)benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxycyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-[2-(4-sulfamoylphenyl)ethyl]benzamide; N-(4-Dimethylaminobenzyl)-2-(3-{(2R)-2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)acetamide; N-[5-(2-{(1R)-2-[3-(3,4-Dihydro-1H-isoquinoline-2-carbonyl)phenyl]-1,1-dimethylethylamino}-1-hydroxyethyl)-2- hydroxyphenyl]formamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-(4'-hydroxybiphenyl-3-ylmethyl)benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-[2-(4-hydroxy-2,5-dimethylphenyl)ethyl] benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-[2-(4-hydroxy-3-methylphenyl)ethyl]benzamide; N-(4-Acetylaminobenzyl)-2-(3-{(2R)-2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)acetamide; 4-{[2-(3-{(2R)-2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)acetylamino]methyl}benzamide; N-Adamantan-1-yl-3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-(2-hydroxynaphthalen-1-ylmethyl)benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-(4-hydroxy-3,5-dimethylbenzyl)benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-(6-hydroxynaphthalen-2-ylmethyl)benzamide; N-(3,6-Dichloro-2-hydroxybenzyl)-3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}benzamide; N-(3,4-Dimethylbenzyl)-2-(3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]ethyl}phenyl)acetamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-[2-(4-hydroxyphenyl)-2-methylpropyl]benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}-N-(4'-hydroxybiphenyl-4-ylmethyl)benzamide; N-Adamantan-1-yl-2-(3-{(2R)-2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)acetamide; N-[5-(2-{2-[3-(10-Azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-triene-10-carbonyl)phenyl]-1,1-dimethylethylamino }-1-hydroxyethyl)-2-hydroxyphenyl]formamide; 2-(3-{(2R)-2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)-N-(4'-hydroxybiphenyl-3-ylmethyl) acetamide; 4-{[2-(3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)acetylamino]methyl}benzoic acid methyl ester; 2-(3-{(2R)-2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)-N-(4-trifluoromethoxybenzyl)acetamide; N-(2-Chloro-4-hydroxybenzyl)-N-ethyl-2-(3-{(2R)-2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]- 2-methylpropyl}phenyl)acetamide; N-(2-Chloro-4-hydroxybenzyl)-2-(3-{(2R)-2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl} phenyl)acetamide; 2-(3-{(2R)-2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)-N-(4-hydroxy-3,5-dimethylbenzyl )acetamide; 2-(3-{(2R)-2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)-N-(2-hydroxynaphthalen-1-ylmethyl)acetamide ; N-(5-Chloro-2-hydroxybenzyl)-2-(3-{(2R)-2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)acetamide ; N-(3,5-Dichloro-2-hydroxybenzyl)-2-(3-{(2R)-2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl )acetamide; 2-(3-{(2R)-2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)-N-(6-hydroxynaphthalen-2-ylmethyl)acetamide ; 2-(3-{(2R)-2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)-N-(4'-hydroxybiphenyl-4-ylmethyl) acetamide; N-(4-Cyanobenzyl)-2-(3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)acetamide; 2-(3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)-N-(4-methanesulfonylbenzyl)acetamide; 2-(3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)-N-(4-methylsulfanylbenzyl)acetamide; 2-(3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)-N-(4-trifluoromethylbenzyl)acetamide; 2-(3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)-N-(4'-hydroxybiphenyl-4-ylmethyl)acetamide ; N-[2-(5-Chloro-2-hydroxyphenyl)ethyl]-3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}benzamide; 2-(3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)-N-(4'-hydroxybiphenyl-3-ylmethyl)acetamide ; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}-N-[2-(4-hydroxyphenyl)-2-methylpropyl]benzamide; N-(2-Chloro-4-hydroxybenzyl)-2-(3-{(2R)-2-[(2R)-(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl }phenyl)acetamide; N-[2-(5-Chloro-2-hydroxyphenyl)ethyl]-3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}benzamide; 3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}-N-[2-(4-hydroxyphenyl)-2-methylpropyl]benzamide; 2-(3-{2-[(2R)-2-(3-Formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)-N-(tetrahydro-thiopyran-4-yl)acetamide; N-(5-Chloro-2-hydroxybenzyl)-2-(3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)acetamide; and N-{5-[(1R)-2-((1R)-2-{3-[3-(3,4-Dihydro-1H-isoquinolin-2-yl)-3-oxopropyl]phenyl}-1- methylethylamino)-1-hydroxyethyl]-2-hydroxyphenyl}formamide. 16. Spoj, naznačen time što je N-(5-klor-2-hidroksibenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid ili njegova farmaceutski prihvatljiva sol ili solvat.16. Compound characterized by N-(5-chloro-2-hydroxybenzyl)-2-(3-{(2R)-2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2 -hydroxyethylamino]propyl}phenyl)acetamide or a pharmaceutically acceptable salt or solvate thereof. 17. Spoj, naznačen time što je 2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(4-hidroksi-3,5-dimetilbenzil)acetamid ili njegova farmaceutski prihvatljiva sol ili solvat.17. A compound characterized by the fact that 2-(3-{(2R)-2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)-N-(4 -hydroxy-3,5-dimethylbenzyl)acetamide or a pharmaceutically acceptable salt or solvate thereof. 18. Spoj, naznačen time što je 2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(6-hidroksinaftalen-2-ilmetil)acetamid ili njegova farmaceutski prihvatljiva sol ili solvat.18. Compound characterized by the fact that 2-(3-{(2R)-2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)-N-(6 -hydroxynaphthalen-2-ylmethyl)acetamide or a pharmaceutically acceptable salt or solvate thereof. 19. Spoj, naznačen time što je 2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(4'-hidroksibifenil-4-ilmetil)acetamid ili njegova farmaceutski prihvatljiva sol ili solvat.19. A compound characterized by the fact that 2-(3-{(2R)-2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]propyl}phenyl)-N-(4 '-Hydroxybiphenyl-4-ylmethyl)acetamide or a pharmaceutically acceptable salt or solvate thereof. 20. Spoj, naznačen time što je N-[2-(4-klorfenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid ili njegova farmaceutski prihvatljiva sol ili solvat.20. A compound characterized in that N-[2-(4-chlorophenyl)ethyl]-3-{2-[(2R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]-2- methylpropyl}benzamide or a pharmaceutically acceptable salt or solvate thereof. 21. Farmaceutski pripravak, naznačen time što u najmanjeu ruku sadrži djelotvornu količinu spoja formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 20 ili njegovu farmaceutski prihvatljivu sol ili izvedeni oblik.21. Pharmaceutical preparation, characterized in that it contains at least an effective amount of the compound of formula (1) in accordance with any of claims 1 to 20 or its pharmaceutically acceptable salt or derivative form. 22. Spoj formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 20 ili njegova farmaceutski prihvatljiva sol, izvedeni oblik ili pripravak, naznačen time što je namijenjen upotrebi kao medikament.22. The compound of formula (1) according to any one of patent claims 1 to 20 or its pharmaceutically acceptable salt, derived form or preparation, indicated by the fact that it is intended for use as a medication. 23. Upotreba spoja formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 20 ili njegove farmaceutski prihvatljive soli, izvedenog oblika ili pripravaka, naznačena time što je navedeni spoj namijenjen proizvodnji lijeka za liječenje bolesti, poremećaja i stanja koje se bira iz skupine koju čine: • astma bilo kojeg tipa, etiologije ili patogeneze, osobito astma koja je član kojeg se bira iz skupine koju čine atopična astma, neatopična astma, alergijska astma, atopična bronhijalna astma posredovana IgE-om, bronhijalna astma, esencijalna astma, prava astma, intrinzična astma, uzrokovana patofiziološkim poremećajima, ekstrinzična astma, uzrokovana čimbenicima iz okoliša, esencijalna astma nepoznatog ili neočiglednog uzroka, neatopična astma, bronhitična astma, emfizematozna astma, astma izazvana fizičkom aktivnošću, astma izazvana alergenima, astma izazvana hladnim zrakom, profesionalna astma, infektivna astma, uzrokovana bakterijskom, gljivičnom, protozojskom ili virusnom infekcijom, nealergijska astma, incipijentna astma, sindrom sopljućeg djeteta i bronhiolitis, • kronična ili akutna bronhokonstrikcija, kronični bronhitis, začepljenje malih dišnih puteva, te emfizem, • opstruktivne ili upalne bolesti dišnih puteva bilo kojeg tipa, etiologije ili patogeneze, osobito opstruktivna ili upalna bolest dišnih puteva koja je član kojeg se bira iz skupine koju čine kronična eozinofilna pneumonija, kronična opstruktivna plućna bolest (COPD), COPD koji uključuje kronični bronhitis, plućni emfizem ili dispneju povezane ili nepovezane s COPD-om, COPD kod kojeg je karakteristično nepovratno, progresivno začepljenje dišnih puteva, sindrom respiratornog distresa kod odraslih (ARDS), pogoršanje preosjetljivosti dišnih puteva zbog terapije drugim lijekovima i bolest dišnih puteva povezana s plućnom hipertenzijom, • bronhitis bilo kojeg tipa, etiologije ili patogeneze, osobito bronhitis koji je član kojeg se bira iz skupine koju čine akutni bronhitis, akutni laringotrahealni bronhitis, arahidni bronhitis, kataralni bronhitis, krupozni bronhitis, suhi bronhitis, infektivni astmatični bronhitis, produktivni bronhitis, stafilokokni ili streptokokni bronhitis i vezikularni bronhitis, • akutna ozljada pluća, • bronhiektazija bilo kojeg tipa, etiologije ili patogeneze, osobito bronhiektazija koja je član kojeg se bira iz skupine koju čine cilindrična bronhiektazija, sakularna bronhiektazija, fuziformna bronhiektazija, kapilarna bronhiektazija, cistična bronhiektazija, suha bronhiektazija i folikularna bronhiektazija.23. The use of the compound of formula (1) in accordance with any of patent claims 1 to 20 or its pharmaceutically acceptable salt, derived form or preparations, characterized in that the said compound is intended for the production of a drug for the treatment of diseases, disorders and conditions selected from groups consisting of: • asthma of any type, etiology or pathogenesis, especially asthma which is a member selected from the group consisting of atopic asthma, non-atopic asthma, allergic asthma, IgE-mediated atopic bronchial asthma, bronchial asthma, essential asthma, true asthma, intrinsic asthma , caused by pathophysiological disorders, extrinsic asthma, caused by environmental factors, essential asthma of unknown or non-obvious cause, non-atopic asthma, bronchitic asthma, emphysematous asthma, asthma caused by physical activity, asthma caused by allergens, asthma caused by cold air, occupational asthma, infectious asthma, caused by bacterial, fungal, protozoal or viral infection, non-allergic asthma, incipient asthma, wheezing child syndrome and bronchiolitis, • chronic or acute bronchoconstriction, chronic bronchitis, blockage of small airways, and emphysema, • obstructive or inflammatory diseases of the respiratory tract of any type, etiology or pathogenesis, in particular obstructive or inflammatory disease of the respiratory tract which is a member selected from the group consisting of chronic eosinophilic pneumonia, chronic obstructive pulmonary disease (COPD), COPD which includes chronic bronchitis, pulmonary emphysema or dyspnea related or unrelated to COPD, COPD characterized by irreversible, progressive airway obstruction, adult respiratory distress syndrome (ARDS), exacerbation of airway hypersensitivity due to therapy with other drugs, and airway disease associated with pulmonary hypertension, • bronchitis of any type, etiology or pathogenesis, especially bronchitis which is a member selected from the group consisting of acute bronchitis, acute laryngotracheal bronchitis, arachidonic bronchitis, catarrhal bronchitis, croupous bronchitis, dry bronchitis, infectious asthmatic bronchitis, productive bronchitis, staphylococcal or streptococcal bronchitis and vesicular bronchitis, • acute lung injury, • bronchiectasis of any type, etiology or pathogenesis, especially bronchiectasis which is a member selected from the group consisting of cylindrical bronchiectasis, saccular bronchiectasis, fusiform bronchiectasis, capillary bronchiectasis, cystic bronchiectasis, dry bronchiectasis and follicular bronchiectasis. 24. Kombinacija spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 20, naznačena time što se navedeni spoj kombinira s jednim ili više drugih terapeutijskih sredstava, koja sebira između: (a) Inhibitora 5-lipoksigenaze (5-LO) ili antagonista 5-lipoksigenaza-aktivirajućeg proteina (FLAP), (b) Leukotrienskim antagonistima (LTRA), uključujući antagoniste LTB4, LTC4, LTD4 i LTE4, (c) Antagonistima histaminskih receptora, uključujući H1 i H3 antagoniste, (d) α1- i α2-adrenoceptorskim vazokonstrikcijskim simpatomimetskim agonistima koje se upotrebljava kao dekongestivi, (e) Antagonistima muskarinskog receptora M3 ili antikolinergičkim sredstvima, (f) Inhibitorima PDE, primjerice inhibitorima PDE3, PDE4 i PDE5, (g) Teofilinom, (h) Natrijevom kromoglikatom, (i) Inhibitorima COX, kako neselektivnim tako i selektivnim inhibitorima COX-1 ili COX-2 (NSAID), (j) Oralnim i inhalacijskim glukokortikosteroidima, (k) Monoklonskim protutijelima aktivnim protiv endogenih upalnih entiteta, (l) Sredstva protiv čimbenika tumorske nekroze (anti-TNF-α), (m) Inhibitorima adhezijskih molekula, uključujući antagoniste VLA-4, (n) Antagonistima kininskih receptora B1 i B2, (o) Imunosupresivnim sredstvima, (p) Inhibitorima matriksnih metaloproteaza (MMP), (q) Antagonistima tahikininskih receptora NK1, NK2 i NK3, (r) Inhibitorima elastaze, (s) Adenosine A2a receptor agonisti, (t) Inhibitorima urokinaze, (u) Spojevima koji djeluju na dopaminske receptore, primjerice D2 agonistima, (v) Modulatorima NFκβ puta, primjerice inhibitorima IKK, (w) Modulatorima citokinskih signalnih puteva, poput p38 MAP kinaze ili syk kinaze, (x) Sredstima koja se može klasificirati kao mukolitike ili antitusike, (y) Antibioticima, (z) Inhibitorima HDAC, i, (aa) Inhibitorima PI3-kinaze.24. The combination of a compound according to any one of claims 1 to 20, characterized in that said compound is combined with one or more other therapeutic agents, which ranges between: (a) 5-lipoxygenase (5-LO) inhibitors or 5-lipoxygenase-activating protein (FLAP) antagonists, (b) Leukotriene antagonists (LTRAs), including LTB4, LTC4, LTD4 and LTE4 antagonists, (c) Histamine receptor antagonists, including H1 and H3 antagonists, (d) α1- and α2-adrenoceptor vasoconstrictor sympathomimetic agonists used as decongestants, (e) M3 muscarinic receptor antagonists or anticholinergic agents, (f) PDE inhibitors, for example PDE3, PDE4 and PDE5 inhibitors, (g) Theophylline, (h) Sodium cromoglycate, (i) COX inhibitors, both non-selective and selective COX-1 or COX-2 inhibitors (NSAIDs), (j) Oral and inhaled glucocorticosteroids, (k) Monoclonal antibodies active against endogenous inflammatory entities, (l) Agents against tumor necrosis factor (anti-TNF-α), (m) Inhibitors of adhesion molecules, including VLA-4 antagonists, (n) Antagonists of kinin receptors B1 and B2, (o) Immunosuppressive agents, (p) Matrix metalloprotease (MMP) inhibitors, (q) Tachykinin receptor antagonists NK1, NK2 and NK3, (r) Elastase inhibitors, (s) Adenosine A2a receptor agonists, (t) urokinase inhibitors, (u) Compounds that act on dopamine receptors, for example D2 agonists, (v) NFκβ pathway modulators, for example IKK inhibitors, (w) Modulators of cytokine signaling pathways, such as p38 MAP kinase or syk kinase, (x) Means that can be classified as mucolytics or antitussives, (y) Antibiotics, (z) HDAC inhibitors, and, (aa) PI3-kinase inhibitors.
HR20100402T 2004-03-23 2010-07-20 Formamide derivatives useful as adrenoceptor HRP20100402T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290767 2004-03-23
GB0425054A GB0425054D0 (en) 2004-03-23 2004-11-12 Formamide derivatives for the treatment of diseases
PCT/IB2005/000619 WO2005092840A1 (en) 2004-03-23 2005-03-10 Formamide derivatives useful as adrenoceptor

Publications (1)

Publication Number Publication Date
HRP20100402T1 true HRP20100402T1 (en) 2010-09-30

Family

ID=35432183

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100402T HRP20100402T1 (en) 2004-03-23 2010-07-20 Formamide derivatives useful as adrenoceptor

Country Status (30)

Country Link
JP (2) JP4033892B2 (en)
KR (1) KR100806478B1 (en)
AR (1) AR050236A1 (en)
AT (1) ATE469121T1 (en)
CA (1) CA2560547C (en)
CY (1) CY1112549T1 (en)
DE (1) DE602005021472D1 (en)
DK (1) DK1730103T3 (en)
DO (1) DOP2005000045A (en)
EA (1) EA010133B1 (en)
ES (1) ES2343808T3 (en)
GB (1) GB0425054D0 (en)
GE (1) GEP20084455B (en)
HN (1) HN2005000118A (en)
HR (1) HRP20100402T1 (en)
IL (1) IL178102A (en)
IS (1) IS8552A (en)
MA (1) MA28480B1 (en)
MX (1) MXPA06011019A (en)
MY (1) MY144103A (en)
NL (1) NL1028597C2 (en)
NO (1) NO20064806L (en)
NZ (1) NZ549839A (en)
PE (1) PE20060264A1 (en)
PT (1) PT1730103E (en)
RS (1) RS51438B (en)
SI (1) SI1730103T1 (en)
SV (1) SV2005002056A (en)
TW (1) TWI335312B (en)
UY (1) UY28819A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2005492A6 (en) * 1987-12-23 1989-03-01 Lasa Lab N-hydroxyphenyl formamide deriv. prepn.
CH686869A5 (en) * 1991-04-05 1996-07-31 Sepracor Inc Improved use of beta-2-sympathomimetic broncho dilators
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
OA11558A (en) * 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6747043B2 (en) * 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
US7317102B2 (en) * 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
ES2293530T3 (en) * 2004-01-22 2008-03-16 Pfizer, Inc. DERIVATIVES OF SULFONAMIDS FOR THE TREATMENT OF DISEASES.
WO2005092861A1 (en) * 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
BRPI0508927A (en) * 2004-03-17 2007-08-14 Pfizer compounds useful for treating diseases
WO2005092887A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
WO2005092841A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity

Also Published As

Publication number Publication date
GEP20084455B (en) 2008-08-10
JP4033892B2 (en) 2008-01-16
IS8552A (en) 2006-10-10
DOP2005000045A (en) 2005-11-15
IL178102A (en) 2011-08-31
UY28819A1 (en) 2005-10-31
KR20060122969A (en) 2006-11-30
RS51438B (en) 2011-04-30
HN2005000118A (en) 2011-02-25
MY144103A (en) 2011-08-15
SI1730103T1 (en) 2010-09-30
GB0425054D0 (en) 2004-12-15
EA200601544A1 (en) 2007-02-27
DE602005021472D1 (en) 2010-07-08
DK1730103T3 (en) 2010-08-16
PT1730103E (en) 2010-07-21
IL178102A0 (en) 2006-12-31
NL1028597C2 (en) 2006-03-06
MXPA06011019A (en) 2007-03-21
EA010133B1 (en) 2008-06-30
TW200531959A (en) 2005-10-01
CY1112549T1 (en) 2015-12-09
ES2343808T3 (en) 2010-08-10
PE20060264A1 (en) 2006-04-01
MA28480B1 (en) 2007-03-01
TWI335312B (en) 2011-01-01
CA2560547C (en) 2011-02-01
NZ549839A (en) 2010-01-29
ATE469121T1 (en) 2010-06-15
NL1028597A1 (en) 2005-09-26
NO20064806L (en) 2006-12-21
SV2005002056A (en) 2005-12-13
AR050236A1 (en) 2006-10-11
JP2007530524A (en) 2007-11-01
JP4819770B2 (en) 2011-11-24
JP2008056680A (en) 2008-03-13
CA2560547A1 (en) 2005-10-06
KR100806478B1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
CA2553789A1 (en) Sulfonamide derivatives for the treatment of diseases
CA2553293A1 (en) Sulfonamide derivatives for the treatment of diseases
JP2006511596A5 (en)
NL1028599C2 (en) Compounds for the treatment of diseases.
JP2007529499A5 (en)
JP3966897B2 (en) (2-Hydroxy-2- (4-hydroxy-3-hydroxymethylphenyl) -ethylamino) -propyl-phenyl derivatives as beta-2 agonists
RU2009118825A (en) 4- (2-AMINO-1HYDROXYETHYL) PHENOL DERIVATIVES AS β2-ADRENERGIC RECEPTOR AGONISTS
HRP20170307T1 (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
CA2623332A1 (en) Carboxamide derivatives as muscarinic receptor antagonists
HRP20170896T1 (en) Pyrimidine derivatives
HRP20100035T1 (en) Crystalline forms of a biphenyl compound
JP4054366B2 (en) Compounds useful for the treatment of diseases
HRP20130174T1 (en) Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis
HRP20151317T1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
JP2010520893A5 (en)
AR037092A1 (en) COMPOUNDS CONTAINING LACTAMA AND DERIVATIVES OF THE SAME AS INHIBITORS OF THE XA FACTOR
CA2560368A1 (en) Compounds for the treatment of diseases
HRP20190668T1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
CA2658359A1 (en) Heterocyclic compounds and methods of use
HRP20100433T1 (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
JP2012523440A5 (en)
HRP20100402T1 (en) Formamide derivatives useful as adrenoceptor
HRP20120069T1 (en) 5.6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as antagonists for urotensine ii receptors
JP2013509376A5 (en)
CA2705729A1 (en) Pyrazole derivatives as 5-lo inhibitors